# Containment of *Candida auris*, Other Multidrug-resistant Organisms (MDRO), and SARS-CoV-2

November 18, 2020

**Presented via Webinar** 

Erin Epson, MD Healthcare-Associated Infections (HAI) Program Center for Health Care Quality California Department of Public Health




#### **Objectives**

- Provide updates on multidrug-resistant organism (MDRO) resurgence in the setting of COVID-19 in California
- Describe healthcare-associated MDRO
- Discuss basic infection control measures to contain MDRO and SARS-CoV-2 transmission in healthcare facilities




#### C. auris Cases Reported in CA through October 31, 2020 (N=636)





#### C. auris, COVID-19 Cases in CA through October 31, 2020 (N=636)






#### **COVID-19-related Challenges in Healthcare Settings**

- Staffing, PPE, alcohol-based hand sanitizer (ABHS), cleaning & disinfectant supply shortages
- Disruptions in routine practices and processes, including infection control
- Healthcare personnel (HCP) safety concerns
- We understand!



#### **HEALTHCARE-ASSOCIATED INFECTIONS PROGRAM**

#### What Can We Do?



Early detection, infection control and public healthcoordinated responses needed to contain spread

Public health teams nationwide can launch early, aggressive responses to contain spread and protect peopleat the first sign of antibiotic resistance, every time.

Find guidance, lab protocols, and more resources: www.cdc.gov/HAI/Outbreaks/MDRO



#### **Healthcare-associated MDRO\*: What We Know**

C. auris	Acinetobacter	Other MDRO (e.g., CRE)	C. diff
Х	Х	Х	Х
х	х	X	Х
х	Х	Х	Х
х	х	Х	Х
Х	Х		Х
Х			
	x x x x x x	X       X         X       X         X       X         X       X         X       X         X       X         X       X         X       X	X         X         X           X         X         X           X         X         X           X         X         X           X         X         X           X         X         X           X         X         X           X         X         X           X         X         X           X         X         X           X         X         X

\*Including Clostridiodes difficile (C. diff)

C. auris=Candida auris; CRE=carbapenem-resistant Enterobacteriaceae



#### **Healthcare-associated MDRO\*:**

#### **Containment, Infection Control Measures**

	C. auris	Acinetobacter	Other MDRO (e.g., CRE)	C. diff
Good hand hygiene – ABHS preferred	х	х	Х	Soap & water
Contact precautions, single room if possible	х	Х	Х	х
Thorough environmental cleaning and disinfection	Use <u>C. auris/</u> List K agent	Х	Х	Use <u>List K</u> agent
Routine adherence monitoring	Х	Х	Х	Х
Cohorting of patients and healthcare personnel	х	х	Х	Х
Lab surveillance	Х	Х	Х	Х
Screening of high-risk contacts *Including Clostridiodes difficile (C. diff)	X ABHS=alcohol-based	X hand sanitizer; C. auris=	X Candida auris; CRE=carbapenem-resista	nt Enterobacter



8

ABHS=alcohol-based hand sanitizer; C. auris=Candida auris; CRE=carbapenem-resistant Enterobacteriaceae

## MDRO\* & SARS-CoV-2: **Containment, Infection Control Measures**

	C. auris	Acinetobacter	Other MDRO (e.g., CRE)	C. diff	SARS-CoV-2
Good hand hygiene – ABHS preferred	х	х	Х	Soap & water	Х
Contact precautions, single room if possible	x	Х	X	Х	+ respirator, eye protection
Thorough environmental cleaning and disinfection	Use <u>C. auris/</u> List K agent	Х	Х	Use <u>List K</u> agent	Use <u>List N agent</u> ( <i>C. auris/</i> List K agent OK)
Routine adherence monitoring	Х	х	Х	Х	Х
Cohorting of patients and healthcare personnel	х	х	Х	Х	Х
Lab surveillance	Х	х	Х	Х	Х
Screening of high-risk contacts *Including Clostridiodes difficile (C. diff)	X ABHS=alcohol-based	X	X Candida auris; CRE=carbapenem-resista	nt Enterobacte	X



#### **Infection Control Basics: Hand Hygiene**

- Use ABHS over soap and water (unless visibly soiled hands/*C. diff*)
- Place ABHS dispensers in as many patient/resident care locations as possible
- More then just gel-in/gel-out; remember the **5 moments**
- Gloves are NOT a substitute for HH; perform HH before donning PPE, after doffing
- Perform adherence monitoring



https://www.who.int/infection-prevention/campaigns/cleanhands/5moments/en/



#### **Infection Control Basics: PPE**

- If no shortages, do not practice extended use or reuse of gowns\* or gloves
- Everyone should adhere, including physicians and ancillary staff
- Double-gowning and -gloving are NOT recommended
- Don/Doff WITH hand hygiene
- Keep signage simple and consistent

\*https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppestrategy/isolation-gowns.html





#### **Infection Control Basics: Transmission-based Precautions**

- Standard precautions +
- Keep it simple, clear signage
- By known organism
- Everyone should adhere, including physicians and ancillary staff
- Perform adherence monitoring


#### **Cohorting patients**

• <u>By known organism</u>, regardless of specimen source, infection or colonization

Contact		<i>C. auris</i> Carbapenem-resistant Enterobacteriaceae (CRE), <i>Pseudomonas, Acinetobacter</i> MRSA, VRE
Contact + Enteric/ Spore		<i>C. difficile</i> Norovirus
Droplet		Influenza
Contact + Respirator + Eye Protection		COVID-19
Airborne	Alir	Tuberculosis Measles Varicella

#### **Infection Control Basics: Environmental Cleaning**

- High-touch surfaces, clean to dirty
- Read labels: know contact time
- Who cleans what: nursing vs EVS
- Adhesives, peeling and cracking surfaces
- Observe and monitor with fluorescent marker, ATP
- Training, re-training
- For *C. auris*, use <u>EPA-registered</u> <u>disinfectant effective against *C.* <u>auris</u>; consider for prevention
  </u>



https://www.cdc.gov/hai/prevent/resource-limited/cleaning-procedures.html




#### Communication

- Key to preventing inter-facility transmission!
- Actively seek MDRO status of all admissions
- Flag medical record for future admissions
- Educate patients and family
- Establish a system between IP, nurse & case manager to ensure clear communication
- Use inter-facility transfer form

HEALTHCARE FACILITY TRANSFER FORM (ABBREVIATED) Use this form for <u>all</u> transfers to an admitting healthcare facility.

Patient Name (Last, First):		
Date of Birth:	MRN:	Transfer Date:
Receiving Facility Name:		
Sending Facility Name:		
Contact Name:		Contact Phone:

#### ISOLATION PRECAUTIONS



ORGANISMS Patient has multidrug-resistant organism (MDRO) or other		
lab results for which the patient should be in isolation?		
Yes No		
If yes, specify organism(s) and include specimen source and		
collection date.		
Organism	Source	Date
C.difficile		
Carbapenem-resistant Enterobacteriaceae (CRE)		
(e.g., Klebsiella, Enterobacter or E.coli)		
Extended-spectrum beta lactam-resistant (ESBL)		
(e.g., E.coli, Klebsiella)		
□ MDR gram negatives (e.g., Acinetobacter, Pseudomonas)		
□ Methicillin-resistant Staphylococcus aureus (MRSA)		
Vancomycin-resistant Enterococcus (VRE)		
□ Other, specify:		
(e.g., lice, scabies, disseminated shingles (Herpes zoster),		
norovirus, influenza, tuberculosis)		

Include copy of **lab results** with organism I.D. and antimicrobial susceptibilities.

https://www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/Interfacilit yCommunication.aspx



#### **Key Messages**

- MDRO transmission in healthcare facilities remains a challenge
- Implementation and reinforcement of basic infection control practices can:
  - Improve patient AND healthcare personnel health and safety
  - Reduce transmission of MDRO AND SARS-CoV-2
- Public health resources are available to support MDRO testing and containment



#### Resources

• CDPH C. auris Quicksheet:

https://www.cdph.ca.gov/Programs/CHCQ/HAI/CDPH%20Document%20Library/C%20auris%20Quicksheet Interim 070720 ADA.pdf

• CDPH CRE Quicksheet:

https://public.staging.cdph.ca.gov/sites/ada/Programs/CHCQ/HAI/CDPH%20Document%20Library/CRE\_QuicksheetOct2019.pdf

- CDPH Carbapenem-resistant *Pseudomonas and Acinetobacter* Quicksheet: <u>https://www.cdph.ca.gov/Programs/CHCQ/HAI/CDPH%20Document%20Library/CRO\_Quicksheet\_Oct2020.pdf</u>
- CDPH Antimicrobial Resistance Resources
   <a href="https://www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/AntimicrobialResistanceLandingPage.aspx">https://www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/AntimicrobialResistanceLandingPage.aspx</a>
- CDPH Enhanced Standard Precautions: <u>https://www.cdph.ca.gov/Programs/CHCQ/LCP/CDPH%20Document%20Library/Enhanced-Standard-Precautions.pdf</u>
- CDPH Adherence Monitoring Tools:

https://www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/MonitoringAdherenceToHCPracticesThatPreventInfection.aspx

- LACDPH Skilled Nursing Facilities: <u>http://publichealth.lacounty.gov/acd/ncorona2019/healthfacilities/snf/prevention/</u>
- AR Lab Network Testing Resources: <u>https://www.cdc.gov/drugresistance/laboratories/AR-lab-network-testing-details.html</u>
- CDC C. auris Identification: <u>https://www.cdc.gov/fungal/candida-auris/identification.html</u>
- CDC Disinfectants Effective against C. auris: <u>https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html#disinfection</u>



#### Acknowledgements

Local Public Health Partners

- Orange County Health Care Agency
- Los Angeles County Department of Public Health

Centers for Disease Control and Prevention



#### **HEALTHCARE-ASSOCIATED INFECTIONS PROGRAM**

#### **Antibiotic Awareness Week**





**HEALTHCARE-ASSOCIATED INFECTIONS PROGRAM** 

## Thank you!

### **Questions?**

For more information, contact

HAIProgram@cdph.ca.gov

